ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements with these filters
Shukra Pharmaceuticals Ltd issued a corrigendum to its Postal Ballot notice regarding the proposed alteration of its Main Object Clause and name change.
Shukra Pharmaceuticals Ltd has filed its 32nd Annual Report for the financial year 2025-26 as mandated by SEBI (LODR) regulations. The document covers the company's annual activities.
Shukra Pharmaceuticals has scheduled its 33rd Annual General Meeting on September 28, 2026, to be held via Video Conferencing.
Shukra Pharmaceuticals Ltd has fixed September 21, 2026, as the record date for a final dividend of ₹0.01 per share. Payment is subject to shareholder approval.
Shukra Pharmaceuticals allotted 11,73,000 equity shares following the conversion of warrants, generating Rs.3.13 Crore in exercise proceeds. This allotment increases the company's paid-up equity capital.
Shukra Pharmaceuticals has issued a postal ballot notice seeking shareholder approval for an amendment to its Memorandum of Association's Object Clause.
Shukra Pharmaceuticals announced the board's approval to change its name to 'Shukra Medtech Limited', alter its main objects, and convene the 33rd Annual General Meeting.
Shukra Pharmaceuticals has scheduled a board meeting on August 22, 2026, to approve the company's name change, object clause alterations, and AGM-related agendas.
Shukra Pharmaceuticals entered a term sheet for a 60:40 strategic joint venture with Borns Medical Robotics. The venture aims to manufacture AI-enabled surgical robotic systems.
Shukra Pharmaceuticals' board approved changing the company name to Shukra Medtech Limited. The board also expanded the company's main business objects to include medical technology activities.
Shukra Pharmaceuticals Limited has successfully listed its equity shares on the National Stock Exchange (NSE) Main Board. The company's shares commenced trading under symbol SHUKRAPHAR on August 14, 2026.
Shukra Pharmaceuticals Limited has announced the direct listing of its equity shares on the NSE Main Board. Trading will commence under the symbol SHUKRAPHAR effective August 14, 2026.
Shukra Pharmaceuticals Ltd reported revenue from operations of ₹23.5 Cr (+335.2% YoY) and net profit of ₹13 Cr (+1200.0% YoY) for Q1 FY27.
The company filed its quarterly shareholding pattern under Regulation 31(1)(a). This report provides the current distribution of shares among promoter and public shareholders.
Shukra Pharmaceuticals Ltd scheduled a board meeting for August 11, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Shukra Pharmaceuticals Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026.
Shukra Pharmaceuticals confirmed receipt of Rs. 0.38 Crore differential consideration for 46.43 lakh warrants. The price was revised from Rs. 34.00 to Rs. 35.56 per warrant.
Shukra Pharmaceuticals held an EOGM on July 6, 2026 via video conference. The meeting approved the issuance of 4,643,000 convertible equity warrants to promoters.
Shukra Pharmaceuticals appointed Mr. Shivkant Dhakad as Company Secretary & Compliance Officer, replacing Ms. Arpita Kabra who resigned. The change ensures continuity in the company's compliance leadership.
Shukra Pharmaceuticals has called an EGM on July 6, 2026 to seek fresh approval for a preferential warrant issue. The move ensures compliance with SEBI ICDR regulations after a prior allotment delay.
Shukra Pharmaceuticals seeks fresh approval for a Rs.16.51 Crore preferential warrant issue to promoters. The move aims to raise capital while complying with SEBI ICDR regulations.
Shukra Pharmaceuticals has scheduled a board meeting for June 10, 2026. Directors will discuss ratifying an allotment resolution and approving a draft postal ballot notice.
Shukra Pharmaceuticals Ltd filed its Annual Secretarial Compliance Report for FY 2025-26. The auditor confirmed statutory compliance despite the company crossing specific regulatory thresholds.
Shukra Pharmaceuticals confirmed zero deviation in utilizing ₹3.95 Crore raised via convertible warrants. The funds support working capital, debt repayment, and capital expenditure.
Shukra Pharmaceuticals Ltd reported revenue from operations of ₹6.3 Cr (-52.6% YoY) and a net loss of ₹1.7 Cr for Q4 FY26.
Shukra Pharmaceuticals approved FY26 audited financial results and recommended a 1% final dividend. The board also allotted 17.35 lakh equity shares upon warrant conversion.
Shukra Pharmaceuticals Ltd clarified that it does not meet the SEBI criteria to be classified as a 'Large Corporate' as of April 2026. The company reported outstanding borrowings of ₹4.17 Crore as of the fiscal year-end.
Shukra Pharmaceuticals Ltd has scheduled a Board Meeting on May 07, 2026. The board will consider audited financial results for the quarter and year ended March 31, 2026, and recommend a final dividend for FY 2025-26.